Vincent Mackay’s Post

Exciting read on the future of AAV gene therapies in 2024! 🧬 Dive into the latest trends and advancements: 🔍 Exploring breakthroughs in AAV vector design. 💊 Impact of novel delivery methods on treatment efficacy. 💡 Insights into regulatory developments shaping the field. 🚀 Opportunities for collaboration and innovation in gene therapy research. #GeneTherapy #HealthcareInnovation #AAVTherapies

Excellent overview piece on current CGT trends. Real-time precision PAT analytics are a vital component in ensuring treatment effectiveness and success, from the accurate measurement of cellular fitness and characterization of donor/starting materials, to the measurement of potency throughout the manufacturing process. Novel precision analytics such as LumaCyte Laser Force Cytology adds additional benefits in easing the challenges around comparability, a very challenging piece of the puzzle. Developers who are considering commercial reimbursement contracts tied to patient treatment success must do everything they can to ensure their product is manufactured at the highest level of effectiveness and consistency. The constant release of draft guidance and now final guidance from the FDA focused on advanced therapy manufacturing and potency marks a turning point for our industry to break through status quo processes and invest in advanced analytics and solutions. The demand ahead for these life changing products is high and to meet this need we all must be laser focused on innovation and investing now in novel technologies and next generation analytics and processes that will ensure these treatments are manufactured at consistent and effective scale.

Cell and Gene Therapies were received with well-deserved excitement, but as they've become more common, biopharmaceutical manufacturers will need to navigate emerging challenges: stricter utilization management, regulatory scrutinity, HTA reassessments, and the ever-present challenge of securing ample uptake. Read my collaboration with Trinity's C&GT experts Ismail Ismailoglu, PhD and Julia Pikus to find out more!

Trinity's perspective on 2024 CGT trends to watch!

Pharmaphorum has just published an article regarding the opportunity costs of #genetherapies and how #exosomes fit into the equation. The article explores gene therapy approvals, and discusses some of the novel approaches the industry is adopting to develop #sustainable, #cost-effective, and #lifesaving gene therapies. https://lnkd.in/dxGTzRju

According to Rare Disease Advisor, “2024 will be a breakout year in addressing key challenges to developing cell and gene therapies, especially for rare disorders.”   Sadly, science continues to outpace the commercialization of innovative therapies while the pharmaceutical industry remains slow to change. As a result, patients are getting lost in the shuffle. At MPATHIK, we’re tackling these shifts head-on with empathy and collaboration.   Learn more about what’s expected in 2024 for gene therapies: https://lnkd.in/eWPSz2Jk

Gene Therapy Market to Register 21.4% CAGR by 2031 | SkyQuest Technology: Gene Therapy Market The gene therapy market is poised for explosive growth, projected to surge from USD 9.0 billion in 2023 to USD 42.46 billion by 2031, reflecting a robust CAGR of 21.4%. Key drivers include advancements in gene silencing, … Continue reading → #Europe #HealthMedicine #PharmaceuticalsBiotech #UK #US

Top 10 Best-Selling Cell and Gene Therapies Ranking cell and gene therapies in terms of revenues shows a fairly stark line between feast and famine. The feast side is well covered in this A-List, which ranks the top 10 therapies according to sales figures from 2023. The famine side begins almost exactly where this A-List ends, but future A-Lists are bound to push famine farther into the background. For more A-Lists by Alex Philippidis visit https://ow.ly/Frza50RypIi

💡 6 steps healthcare leaders should consider before launching a cell and gene therapy program 💡 These therapies are truly life-changing - life-saving - therapies. This is an insightful article from Alexander Pham from Clearway Health. "While new gene therapies are shown to be very promising, the full clinical impact of these treatments is not yet known, driving questions on coverage, cost efficiency and delivery." "It is essential for healthcare institutions to adequately assess their readiness to deliver a cell and gene therapy program by conducting a thorough evaluation of their capabilities and strategic inclinations towards market entry."

🚨 New Article Alert: "Securing Access for Gene Therapies: Challenges, Strategies, and Future Outlook" by Güvenç Koçkaya 🚨 Gene therapies hold immense potential to revolutionize the treatment of genetic disorders, offering life-changing cures for patients worldwide. However, the road to ensuring broad and equitable access is filled with challenges. 🌍 In our latest article, we delve into the key challenges and strategies needed to overcome barriers and make gene therapies accessible for all. Topics covered include: ✅ High costs and economic burden ✅ Complex regulatory and reimbursement pathways ✅ Manufacturing challenges ✅ Uncertainty around long-term effects ✅ The role of innovative payment models, regulatory reforms, public-private partnerships, and patient support programs By addressing these critical issues, we aim to shed light on the future of gene therapy access and explore how global collaboration and technological advancements can lead the way. 🔗 Click the link to read the full article and join the discussion on the future of healthcare! https://lnkd.in/gmKStVzD #GeneTherapy #HealthcareAccess #Biotechnology #HealthEconomics #RegulatoryAffairs #Innovation #MarketAccess #HealthcareStrategies #LifeSciences